Abstract
The discovery of acetylcholinesterase inhibitors is important for the treatment of Alzheimer’s disease (AD), known as the most common type of dementia. Due to the side effects of commonly used acetylcholinesterase inhibitors, studies for the detection of new inhibitors are increasing day by day. In this study, we investigated the effects of some sulfonamide derivatives (S1–S4 and S1i–S4i) on AChE enzymes. The best pose of the active compounds to understand the mechanism of possible inhibition in interaction of enzyme-sulfonamide derivative were performed docking studies after in vitro experimental results. ADME-related physicochemical and pharmacokinetic properties of the synthesized 4-aminobenzenesulfonamide derivatives were the compatibility with Lipinski’s rule of five. We found that the synthesized derivatives of sulfonamides show potential inhibitor properties for AChE with Ki constants in the range of 2.54 ± 0.22–299.60 ± 8.73 µM. The derivatives of sulfonamides exhibited different inhibition type. We determined that the derivatives (S1, S1i, S3, and S3i) showed a competitive inhibition effect, whereas others (S2, S2i, S4, and S4i) showed mixed-type inhibition. As a result, the sulfonamide derivatives can be used as an alternative acetylcholinesterase inhibitor due to this effect. Inhibitors with fewer side effects, are thought to be important in the treatment of AD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andreani A et al (2001) Synthesis and screening for antiacetylcholinesterase activity of (1-benzyl-4-oxopiperidin-3-ylidene) methylindoles and-pyrroles related to donepezil. J Med Chem 44:4011–4014. https://doi.org/10.1021/jm0109356
Bag S et al (2015) Sulfonamides as multifunctional agents for Alzheimer’s disease. Bioorg Med Chem Lett 25:626–630. https://doi.org/10.1016/j.bmcl.2014.12.006
Bartolini M, Bertucci C, Cavrini V, Andrisano V (2003) β-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem Pharmacol 65:407–416. https://doi.org/10.1016/S0006-2952(02)01514-9
Belluti F et al (2009) Design, synthesis, and evaluation of benzophenone derivatives as novel acetylcholinesterase inhibitors. Eur J Med Chem 44:1341–1348. https://doi.org/10.1016/j.ejmech.2008.02.035
Benzi G, Moretti A (1998) Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer’s disease? Eur J Pharmacol 346:1–13. https://doi.org/10.1016/S0014-2999(98)00093-4
Beydemir Ş, Türkeş C, Yalçın A (2019) Gadolinium-based contrast agents: in vitro paraoxonase 1 inhibition, in silico studies. Drug Chem Toxicol. https://doi.org/10.1080/01480545.2019.1620266
Caglayan C, Demir Y, Kucukler S, Taslimi P, Kandemir FM, Gulçin İ (2019) The effects of hesperidin on sodium arsenite-induced different organ toxicity in rats on metabolic enzymes as antidiabetic and anticholinergics potentials: a biochemical approach. J Food Biochem 43:e12720. https://doi.org/10.1111/jfbc.12720
Çağlayan C, Taslimi P, Demir Y, Küçükler S, Kandemir FM, Gulçin İ (2019) The effects of zingerone against vancomycin-induced lung, liver, kidney and testis toxicity in rats: the behavior of some metabolic enzymes. J Biochem Mol Toxicol. https://doi.org/10.1002/jbt.22381
Choudhary MI (2001) Bioactive natural products as a potential source of new pharmacophores. A theory of memory. Pure Appl Chem 73:555–560. https://doi.org/10.1351/pac200173030555
Davis T (1976) Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 2:1403
de Oliveira AS et al (2016) New sulfonamides derived from carvacrol: compounds with high antibacterial activity against resistant staphylococcus aureus strains. J Biosci Med 4:105. https://doi.org/10.4236/jbm.2016.47011
Demir Y, Işık M, Gülçin İ, Beydemir Ş (2017) Phenolic compounds inhibit the aldose reductase enzyme from the sheep kidney. J Biochem Mol Toxicol 31:e21936. https://doi.org/10.1002/jbt.21935
Durgun M, Turkmen H, Ceruso M, Supuran CT (2016) Synthesis of 4-sulfamoylphenyl-benzylamine derivatives with inhibitory activity against human carbonic anhydrase isoforms I, II, IX and XII. Bioorg Med Chem 24:982–988. https://doi.org/10.1016/j.bmc.2016.01.020
Ellman GL, Courtney KD, Andres V Jr, Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88–95. https://doi.org/10.1016/0006-2952(61)90145-9
Erdemir F et al (2019) Novel 2-aminopyridine liganded Pd (II) N-heterocyclic carbene complexes: synthesis, characterization, crystal structure and bioactivity properties. Bioorg Chem 91:103134. https://doi.org/10.1016/j.bioorg.2019.103134
Eroglu E, Türkmen H (2007) A DFT-based quantum theoretic QSAR study of aromatic and heterocyclic sulfonamides as carbonic anhydrase inhibitors against isozyme, CA-II. J Mol Graph Model 26:701–708. https://doi.org/10.1016/j.jmgm.2007.03.015
Friesner RA et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739–1749. https://doi.org/10.1021/jm0306430
García-Ayllón M-S, Small DH, Avila J, Sáez-Valero J (2011) Revisiting the role of acetylcholinesterase in Alzheimer’s disease: cross-talk with P-tau and β-amyloid. Front Mol Neurosci 4:22. https://doi.org/10.3389/fnmol.2011.00022
Genç Y, Özkanca R, Bekdemir Y (2008) Antimicrobial activity of some sulfonamide derivatives on clinical isolates of Staphylococus aureus. Ann Clin Microbiol Antimicrob 7:17. https://doi.org/10.1186/1476-0711-7-17
Geula C, Mesulam M (1989) Special properties of cholinesterases in the cerebral cortex of Alzheimer’s disease. Brain Res 498:185–189. https://doi.org/10.1016/0006-8993(89)90419-8
Göçer H, Akincioğlu A, Göksu S, Gülçin İ, Supuran CT (2015) Carbonic anhydrase and acetylcholinesterase inhibitory effects of carbamates and sulfamoylcarbamates. J Enzyme Inhib Med Chem 30:316–320. https://doi.org/10.3109/14756366.2014.928704
Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, Banks JL (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47:1750–1759. https://doi.org/10.1021/jm030644s
Harder E et al (2015) OPLS3: a force field providing broad coverage of drug-like small molecules and proteins. J Chem Theory Comput 12:281–296. https://doi.org/10.1021/acs.jctc.5b00864
Ignasik M, Bajda M, Guzior N, Prinz M, Holzgrabe U, Malawska B (2012) Design, synthesis and evaluation of novel 2-(aminoalkyl)-isoindoline-1, 3-dione derivatives as dual-binding site acetylcholinesterase inhibitors. Arch Pharm 345:509–516. https://doi.org/10.1002/ardp.201100423
Imbimbo BP (2001) Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer’s disease. CNS Drugs 15:375–390. https://doi.org/10.2165/00023210-200115050-00004
Işık M (2019) The binding mechanisms and inhibitory effect of intravenous anesthetics on AChE in vitro and in vivo: kinetic analysis and molecular docking. Neurochem Res. https://doi.org/10.1007/s11064-019-02852-y
Işık M, Demir Y, Kırıcı M, Demir R, Şimşek F, Beydemir Ş (2015) Changes in the anti-oxidant system in adult epilepsy patients receiving anti-epileptic drugs. Arch Physiol Biochem 121:97–102. https://doi.org/10.3109/13813455.2015.1026912
Işık M, Beydemir Ş, Yılmaz A, Naldan ME, Aslan HE, Gülçin İ (2017) Oxidative stress and mRNA expression of acetylcholinesterase in the leukocytes of ischemic patients. Biomed Pharmacother 87:561–567. https://doi.org/10.1016/j.biopha.2017.01.003
Köksal Z, Alım Z, Bayrak S, Gülçin İ, Özdemir H (2019) Investigation of the effects of some sulfonamides on acetylcholinesterase and carbonic anhydrase enzymes. J Biochem Mol Toxicol 33:e22300. https://doi.org/10.1002/jbt.22300
Kołaczek A, Fusiarz I, Ławecka J, Branowska D (2014) Biological activity and synthesis of sulfonamide derivatives: a brief review. Chemik 68:620–628
Kucukoglu K, Gul HI, Taslimi P, Gulcin I, Supuran CT (2019) Investigation of inhibitory properties of some hydrazone compounds on hCA I, hCA II and AChE enzymes. Bioorg Chem 86:316–321. https://doi.org/10.1016/j.bioorg.2019.02.008
Lineweaver H, Burk D (1934) The determination of enzyme dissociation constants. J Am Chem Soc 56:658–666. https://doi.org/10.1021/ja01318a036
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3–25. https://doi.org/10.1016/S0169-409X(96)00423-1
Liston DR et al (2004) Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer’s disease. Eur J Pharmacol 486:9–17. https://doi.org/10.1016/j.ejphar.2003.11.080
Martinez A, Fernandez E, Castro A, Conde S, Rodriguez-Franco I, Baños J-E, Badia A (2000) N-Benzylpiperidine derivatives of 1, 2, 4-thiadiazolidinone as new acetylcholinesterase inhibitors. Eur J Med Chem 35:913–922. https://doi.org/10.1016/S0223-5234(00)01166-1
Mukherjee PK, Kumar V, Mal M, Houghton PJ (2007) Acetylcholinesterase inhibitors from plants. Phytomedicine 14:289–300. https://doi.org/10.1016/j.phymed.2007.02.002
Mutahir S et al (2016) Novel biphenyl bis-sulfonamides as acetyl and butyrylcholinesterase inhibitors: synthesis, biological evaluation and molecular modeling studies. Bioorg Chem 64:13–20. https://doi.org/10.1016/j.bioorg.2015.11.002
Oh M, Houghton P, Whang W, Cho J (2004) Screening of Korean herbal medicines used to improve cognitive function for anti-cholinesterase activity. Phytomedicine 11:544–548. https://doi.org/10.1016/j.phymed.2004.03.001
Parihar MS, Hemnani T (2004) Alzheimer’s disease pathogenesis and therapeutic interventions. J Clin Neurosci 11:456–467. https://doi.org/10.1016/j.jocn.2003.12.007
Rusted JM, Warburton DM (1992) Facilitation of memory by post-trial administration of nicotine: evidence for an attentional explanation. Psychopharmacology 108:452–455. https://doi.org/10.1007/BF02247420
Sakkiah S, Lee KW (2012) Pharmacophore-based virtual screening and density functional theory approach to identifying novel butyrylcholinesterase inhibitors. Acta Pharmacol Sin 33:964. https://doi.org/10.1038/aps.2012.21
Santos MA, Marques SM, Tuccinardi T, Carelli P, Panelli L, Rossello A (2006) Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors. Bioorg Med Chem 14:7539–7550. https://doi.org/10.1016/j.bmc.2006.07.011
Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27:221–234. https://doi.org/10.1007/s10822-013-9644-8
Schätz CR, Geula C, Mesulam M (1990) Competitive substrate inhibition in the histochemistry of cholinesterase activity in Alzheimer’s disease. Neurosci Lett 117:56–61. https://doi.org/10.1016/0304-3940(90)90119-T
Scozzafava A, Mastrolorenzo A, Supuran CT (2002) Sulfonamides and sulfonylated derivatives as anticancer agents. Curr Cancer Drug Targets 2:55–75. https://doi.org/10.2174/1568009023334060
Singh M, Kaur M, Kukreja H, Chugh R, Silakari O, Singh D (2013) Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection. Eur J Med Chem 70:165–188. https://doi.org/10.1016/j.ejmech.2013.09.050
Turkan F, Cetin A, Taslimi P, Gulçin İ (2018) Some pyrazoles derivatives: potent carbonic anhydrase, α-glycosidase, and cholinesterase enzymes inhibitors. Arch Pharm 351:1800200. https://doi.org/10.1002/ardp.201800200
Türkan F, Huyut Z, Demir Y, Ertaş F, Beydemir Ş (2019) The effects of some cephalosporins on acetylcholinesterase and glutathione S-transferase: an in vivo and in vitro study. Arch Physiol Biochem 125:235–243. https://doi.org/10.1080/13813455.2018.1452037
Türkeş C (2019a) A potential risk factor for paraoxonase 1: in silico and in-vitro analysis of the biological activity of proton-pump inhibitors. J Pharm Pharmacol 71:1553–1564. https://doi.org/10.1111/jphp.13141
Türkeş C (2019b) Investigation of potential paraoxonase-I inhibitors by kinetic and molecular docking studies: chemotherapeutic drugs. Protein Pept Lett 26:392–402. https://doi.org/10.2174/0929866526666190226162225
Türkeş C (2019c) Inhibition effects of phenolic compounds on human serum paraoxonase-1 enzyme. J Inst Sci Technol 9:1013–1022. https://doi.org/10.21597/jist.491054
Türkeş C, Beydemir Ş (2019) Inhibition of human serum paraoxonase-I with antimycotic drugs: in vitro and in silico studies. Appl Biochem Biotechnol. https://doi.org/10.1007/s12010-019-03073-3
Türkeş C, Söyüt H, Beydemir Ş (2014) Effect of calcium channel blockers on paraoxonase-1 (PON1) activity and oxidative stress. Pharmacol Rep 66:74–80. https://doi.org/10.1016/j.pharep.2013.08.007
Türkeş C, Söyüt H, Beydemir Ş (2015) Human serum paraoxonase-1 (hPON1): in vitro inhibition effects of moxifloxacin hydrochloride, levofloxacin hemihidrate, cefepime hydrochloride, cefotaxime sodium and ceftizoxime sodium. J Enzyme Inhib Med Chem 30:622–628. https://doi.org/10.3109/14756366.2014.959511
Türkeş C, Söyüt H, Beydemir Ş (2016) In vitro inhibitory effects of palonosetron hydrochloride, bevacizumab and cyclophosphamide on purified paraoxonase-I (hPON1) from human serum. Environ Toxicol Pharmacol 42:252–257. https://doi.org/10.1016/j.etap.2015.11.024
Türkeş C, Arslan M, Demir Y, Çoçaj L, Nixha AR, Beydemir Ş (2019a) Synthesis, biological evaluation and in silico studies of novel N-substituted phthalazine sulfonamide compounds as potent carbonic anhydrase and acetylcholinesterase inhibitors. Bioorg Chem 89:103004. https://doi.org/10.1016/j.bioorg.2019.103004
Türkeş C, Beydemir Ş, Küfrevioğlu Öİ (2019b) In vitro and in silico studies on the toxic effects of antibacterial drugs as human serum paraoxonase 1 inhibitor. ChemistrySelect 4:9731–9736. https://doi.org/10.1002/slct.201902424
Türkeş C, Demir Y, Beydemir Ş (2019c) Anti-diabetic properties of calcium channel blockers: inhibition effects on aldose reductase enzyme activity. Appl Biochem Biotechnol 189:318–329. https://doi.org/10.1007/s12010-019-03009-x
von Bernhardi R, Alarcón R, Mezzano D, Fuentes P, Inestrosa NC (2005) Blood cells cholinesterase activity in early stage Alzheimer’s disease and vascular dementia. Dement Geriatr Cogn Disord 19:204–212. https://doi.org/10.1159/000083500
Wager TT, Chandrasekaran RY, Hou X, Troutman MD, Verhoest PR, Villalobos A, Will Y (2010) Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chem Neurosci 1:420–434. https://doi.org/10.1021/cn100007x
Weinstock M (1999) Selectivity of cholinesterase inhibition. CNS Drugs 12:307–323. https://doi.org/10.2165/00023210-199912040-00005
Yamali C, Gul HI, Ece A, Taslimi P, Gulcin I (2018) Synthesis, molecular modeling, and biological evaluation of 4-[5-aryl-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl] benzenesulfonamides toward acetylcholinesterase, carbonic anhydrase I and II enzymes. Chem Biol Drug Des 91:854–866. https://doi.org/10.1111/cbdd.13149
Yiğit B, Yiğit M, Taslimi P, Gök Y, Gülçin İ (2018) Schiff bases and their amines: synthesis and discovery of carbonic anhydrase and acetylcholinesterase enzymes inhibitors. Arch Pharm 351:1800146. https://doi.org/10.1002/ardp.201800146
Acknowledgements
The authors are grateful for the financial support provided by the Research Foundation of Harran University (Project no. 16180).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Işık, M., Demir, Y., Durgun, M. et al. Molecular docking and investigation of 4-(benzylideneamino)- and 4-(benzylamino)-benzenesulfonamide derivatives as potent AChE inhibitors. Chem. Pap. 74, 1395–1405 (2020). https://doi.org/10.1007/s11696-019-00988-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11696-019-00988-3